Efficacy and Safety of Fluticasone Propionate Nebulized Suspension for Wheezing Diseases in Infants Aged 0-24 Months (FPNS-IWD)
A Multicenter Clinical Study on Efficacy and Safety of Fluticasone Propionate Nebulized Suspension in the Treatment of Wheezing Diseases in Infants Aged 0-24 Months
This study looks at how well and how safe fluticasone propionate nebulized suspension works in babies aged 0 to 24 months who have acute wheezing.
Investigators will compare it to budesonide nebulized suspension, another approved inhaled steroid.
About 240 babies will join. Participants will be put into two groups by chance (1:1 randomization):
One group gets fluticasone propionate 0.5 mg twice a day by nebulizer The other group gets budesonide 1 mg twice a day by nebulizer Treatment lasts 5 to 7 days. Investigators will check breathing symptoms (wheezing, cough, phlegm, wheeze sounds in lungs) every day during treatment.
The study will check if fluticasone works as well as budesonide (non-inferiority) and may also check if it works better. Safety will be watched closely, including side effects, general health, and lab tests.
This study will help doctors know if fluticasone propionate nebulized suspension is a good treatment option for young babies with wheezing.
調査の概要
状態
研究の種類
入学 (推定)
段階
- フェーズ 4
連絡先と場所
研究連絡先
- 名前:Jianguo Hong, Doctor
- 電話番号:+86 18730251574
- メール:hongjianguo@hotmail.com
参加基準
適格基準
就学可能な年齢
- 子
健康ボランティアの受け入れ
説明
Inclusion Criteria:
- Age: 0-24 months, gender unlimited;
- Clinical diagnosis: infantile wheezing, with the diagnostic criteria referring to Zhu Futang Practical Pediatrics (9th Edition);
- Inpatients with acute clinical manifestations including wheezing, cough, sputum, and bilateral lung wheezes (wheezing and wheezes are mandatory), and the total score of wheezing symptoms and signs (including wheezing + wheezes) ≥ 2 points;
- The onset of the above wheezing symptoms is within 72 hours;
- The guardian of the subject consents and signs the informed consent form.
Exclusion Criteria:
- Children with a clear diagnosis of congenital heart disease (excluding patent ductus arteriosus or patent foramen ovale), primary immunodeficiency, bronchopulmonary dysplasia, bronchiectasis, foreign bodies in the bronchi, pulmonary tuberculosis, or other congenital malformations that may cause wheezing diseases;
- Those with comorbid primary diseases of the circulatory system, digestive system, urinary system, endocrine system, hematopoietic system, and immune system;
- Those with severe respiratory insufficiency;
- Those allergic to the study drugs;
- Those who have received systemic hormone therapy during the current episode of the disease are not eligible for enrollment;
Before enrollment, any one of the laboratory test indicators meets the following criteria: Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) > 2 times the Upper Limit of Normal (ULN) (refer to the normal reference range of laboratory tests in the participating research center); Serum Creatinine (Scr)
- the Upper Limit of Normal.
- Those who have participated in other clinical trials within the past 90 days are not eligible for enrollment;
- Those who the researcher deems unsuitable for participating in the clinical trial are not eligible for enrollment.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:FPN
0.5mg/2ml, BID
|
0.5mg/2ml, BID
|
|
アクティブコンパレータ:BUD
1mg/2ml, BID
|
1mg/2ml, BID
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change from baseline in total wheezing symptom score (wheezing, cough, phlegm, wheeze rales) at Day 5 to Day 7
時間枠:From baseline to Day 5 to Day 7 of treatment
|
Change from baseline in total wheezing symptom score (wheezing, cough, phlegm, wheeze rales) at Day 5 to Day 7 Infant Wheezing Symptom and Sign Grading Quantitative Scale, score range: 0-12 points, higher scores indicate more severe wheezing symptoms and signs.
|
From baseline to Day 5 to Day 7 of treatment
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change from baseline in wheezing symptom and sign score (wheezing, cough, sputum, wheeze rales) at 24 hours, 48 hours and Day 3 of treatment
時間枠:From baseline to 24 hours, 48 hours and Day 3 of treatment
|
Change from baseline in wheezing symptom and sign score (wheezing, cough, sputum, wheeze rales) at 24 hours, 48 hours and Day 3 of treatment Infant Wheezing Symptom and Sign Grading Quantitative Scale, score range: 0- 12 points, higher scores indicate more severe wheezing symptoms and signs.
|
From baseline to 24 hours, 48 hours and Day 3 of treatment
|
|
Therapeutic efficacy of wheezing disease at 24 hours, 48 hours, Day 3, Day 5 to Day 7 of treatment
時間枠:From baseline to 24 hours, 48 hours, Day 3, Day 5 to Day 7 of treatment
|
Therapeutic efficacy of wheezing disease at 24 hours, 48 hours, Day 3, Day 5 to Day 7 of treatment. Efficacy is evaluated using an investigator-defined 4-level clinical efficacy scale based on changes in the total score of the Infant Wheezing Symptom and Sign Grading Quantitative Scale (score range: 0-12; higher scores indicate more severe symptoms and signs). Clinical Cure: Complete resolution of clinical symptoms and signs; reduction in total score ≥90%. Marked Improvement: Substantial resolution of clinical symptoms and signs; reduction in total score ≥60% to <90%. Improvement: Partial resolution or improvement of clinical symptoms and signs; reduction in total score ≥30% to <60%. No Improvement: Does not meet the above criteria. Overall Response Rate = (Number of participants with Clinical Cure + Marked Improvement + Improvement) / Total number of participants. |
From baseline to 24 hours, 48 hours, Day 3, Day 5 to Day 7 of treatment
|
|
Length of hospital stay
時間枠:up to 7 days
|
Comparison of hospital stay days
|
up to 7 days
|
|
Usage of combined rescue drugs
時間枠:up to 7 days
|
including the specific drug name, prescribed dosage, detailed administration method and dosage , and specific administration time.
|
up to 7 days
|
協力者と研究者
捜査官
- 主任研究者:Jianguo Hong, Doctor、Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- 主任研究者:Jiujun Li, Doctor、Shengjing Hospital
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- FPNS-IWD
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。